Manufacturer record

Protech Telelinks Mouza Ogli: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

4 batches manufactured by Protech Telelinks Mouza Ogli (Himachal Pradesh) were declared Not of Standard Quality between September 2025 and November 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

4 records linked to Protech Telelinks Mouza Ogli in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
4Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Sep 2025 to Nov 2025

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

4
NSQ batches since 2025
2
Products affected
Description
Most common failure
Nov 2025
Latest alert

Flagged batches per year

2025 · 4

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Bupivacaine Injection IP L2022410BMfg 2024-10 · Exp 2026-09 The sample does not conform to IP with respect to test for 'Particulate Matter' and is also not of standard quality for the reason stated under "Description".Description CDL, KolkataCDSCO lab Nov 2025
Bupivacaine Injection IP L2022410BMfg 2024-10 · Exp 2026-09 The sample does not conform to claim as per IP 2022 in respect to the Test of Particulate matter, DescriptionDescription CDL, KolkataCDSCO lab Oct 2025
Bupivacaine Injection IP L2022410BMfg 2024-10 · Exp 2026-09 sample does not conform to IP with respect to test for "Particulate matter" and "Description".Description CDL, KolkataCDSCO lab Sep 2025
Amoxycillin & Potassium Clavulanate Injection IP 1200 mg D0092461AMfg 2024-12 · Exp 2026-11 sample does not conform to IP with respect to the Assay of Clavulanic AcidAssay CDL, KolkataCDSCO lab Sep 2025

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.